Pancreatic Enzyme Replacement Therapy
The question
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the supply of Creon; and what support his Department is providing to patients who are not able to use alternative medicines.
Answered by Karin Smyth
The Department continues to engage with suppliers of Creon and other pancreatic enzyme replacement therapies (PERT) to boost production to mitigate the supply issue. The supplier of Creon expects to receive increased quantities for 2025. Suppliers of alternative PERT and specialist importers of unlicensed medicines continue to supply increased volumes to assist in covering the gap in the market. The Department has issued management advice to healthcare professionals which directs clinicians to unlicensed imports when licensed stock is unavailable, and which includes actions for integrated care boards to ensure local mitigation plans are implemented. The Department, in collaboration with NHS England, has created a webpage to include the latest update on PERT availability and easily accessible prescribing advice for clinicians.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →